A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

March 17, 2023

Study Completion Date

October 12, 2023

Conditions
Thyroid Eye DiseaseChronic (Inactive) Thyroid Eye Disease
Interventions
BIOLOGICAL

TEPEZZA

Intravenous infusion

DRUG

Placebo

Intravenous infusion

Trial Locations (12)

29605

Endocrinology Specialists & Thyroid Center, Greenville

33136

Bascom Palmer Eye Institute / Univ of Miami, Miami

38163

Hamilton Eye Institute / U Tennessee, Memphis

52336

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

63108

Washington University, St Louis

77401

Neuro-Eye Clinical Trials, Houston

80045

Univ of Colorado Dept of Ophthalmology, Aurora

89074

Las Vegas Endocrinology, Las Vegas

90048

MACRO Trials, Los Angeles

90210

The Private Practice of Raymond Douglas, Beverly Hills

92037

Perlman Medical Offices / UCSD, La Jolla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT04583735 - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease | Biotech Hunter | Biotech Hunter